BACKGROUND AND PURPOSE:

• Fexofenadine hydrochloride (trade name Allegra Allergy)
  • H1-receptor antagonist | Over the counter
  • Indicated for relief of symptoms associated with seasonal allergic rhinitis
• Cetirizine hydrochloride (trade name Zyrtec Allergy) and loratadine ( trade name Claritin) are recommended as first-line choice of second-generation antihistamines for use during pregnancy by multiple US and international associations
• Andersson et al. (JAMA Pediatrics, 2020) investigated whether fexofenadine use during pregnancy is associated with an increased risk for adverse fetal outcomes

METHODS:

• Nationwide registry-based cohort study
• Participants
  • Pregnancies in Denmark (January 1, 2001 to December 31, 2016)
• Exposures
  • Filled prescription for fexofenadine
• Study design
  • Pregnancy use of fexofenadine hydrochloride vs cetirizine hydrochloride use were compared
  • Fexofenadine and cetirizine were matched in a 1:1 ratio
  • Sensitivity analyses performed, comparing pregnancies with vs without fexofenadine exposure
  • Also compared fexofenadine exposure with
    • Previous fexofenadine use before pregnancy
    • Loratadine use during pregnancy
• Statistical analysis
  • Logistic regression used to estimate prevalence odds ratios (ORs) of major birth defects, preterm birth, and SGA
  • Cox proportional hazards regression was used to estimate hazard ratios (HRs) of spontaneous abortion and stillbirth
• Primary outcomes
  • Major birth defects
  • Spontaneous abortion
• Secondary outcomes
  • Preterm birth
  • SGA
  • Stillbirth

RESULTS:

• 1,287,668 pregnancies
  • Fexofenadine use: 2962 pregnancies
    • Mean (SD) age for analyses of major birth defects: 30.6 (4.8) years
    • Mean (SD) age for analyses of spontaneous abortion: 30.4 (5.5) years
  • Cetirizine use: 4901 pregnancies
• Fexofenadine use was not associated with an increased risk of major birth defects compared to cetirizine
  • Fexofenadine use: 4.0% (118 pregnancies)
  • Cetirizine use: 3.8% (112 pregnancies)
  • OR 1.06 (95% CI 0.81 to 1.37)
• Fexofenadine use during pregnancy was not associated with an increased risk of spontaneous abortion compared to cetirizine
  • Fexofenadine use: 8.4% (413 pregnancies)
  • Cetirizine use: 9.0% (439 pregnancies)
  • HR 0.93 (95% CI 0.82 to 1.07)
• Fexofenadine use was also not associated with an increased risk of the secondary outcomes
  • Preterm birth
    • Fexofenadine use: 7.5% (370 pregnancies)
    • Cetirizine use: 7.7% (382 pregnancies)
    • OR 0.97 (95% CI 0.83 to 1.12)
  • SGA
    • Fexofenadine use: 10.1% (515 pregnancies)
    • Cetirizine use: 10.2% (523 pregancies)
    • OR 0.98 (95% CI 0.87 to 1.12)
  • Stillbirth
    • Fexofenadine use: 0.3% (16 pregnancies)
    • Cetirizine use: 0.4% (24 pregnancies)
    • HR 0.67 (95% CI 0.36 to 1.27)
• Sensitivity analyses showed similar results (no associations) including comparisons of fexofenadine exposure vs
  • Pregnancies with loratadine use
  • Pregnancies unexposed to fexofenadine during pregnancy but with prior fexofenadine use

CONCLUSION:

• The results of this study did not demonstrate an increased risk of adverse fetal outcomes with fexofenadine use during pregnancy
• The authors state

…we suggest that fexofenadine can be used as equally as the other recommended antihistamines during pregnancy

Learn More – Primary Sources:

Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes

Related ObG Topics:

Ondansetron for Nausea During Pregnancy – Is There a Risk for Birth Defects?

Is Macrolide Antibiotic Use During Pregnancy Linked to Increased Risk of Congenital Malformations?

Do Antidepressants During Pregnancy Increase Autism Risk?

SMFM Releases Statement on Acetaminophen Use in Pregnancy

Adverse Perinatal Outcomes and Epilepsy: Is it the Disorder or the Treatment?